Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Abstract
Summary
According to the recently published report 'Collagenase 3 - Drugs In Development, 2022'; Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes.
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Collagenase-3 (MMP13) is a member of the matrix metalloproteinase (MMP) family of neutral endopeptidases. It plays a role in the degradation of extracellular matrix proteins including fibrillar collagen, fibronectin, TNC and ACAN, wound healing, tissue remodeling, cartilage degradation, bone development, bone mineralization and ossification.
The report 'Collagenase 3 - Drugs In Development, 2022' outlays comprehensive information on the Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Preclinical and Discovery stages are 1, 2 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Musculoskeletal Disorders, Cardiovascular, Central Nervous System, Genetic Disorders, Infectious Disease, Oncology, Respiratory and Toxicology which include indications Osteoarthritis, Osteoarthritis Pain, Allergic Asthma, Alphavirus Infections, Arthralgia (Joint Pain), Arthritis, Chemotherapy Induced Peripheral Neuropathy, Chikungunya Fever, Congestive Heart Failure (Heart Failure), Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome, Edema, Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ), Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ), Multiple Myeloma (Kahler Disease), Myocardial Infarction and Seasonal Allergic Rhinitis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.)
- The report reviews Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics and enlists all their major and minor projects
- The report assesses Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Content
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Overview
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Companies Involved in Therapeutics Development
Aquilus Pharmaceuticals Inc
Avantyx Pharmaceuticals LLC
Paradigm Biopharmaceuticals Ltd
Pharmahungary Group
SteroTherapeutics LLC
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Drug Profiles
Antisense RNAi Oligonucleotides to Inhibit MMP-13 for Osteoarthritis - Drug Profile
Product Description
Mechanism Of Action
Drug to Inhibit MMP-13 for Chemotherapy Induced Peripheral Neuropathy - Drug Profile
Product Description
Mechanism Of Action
History of Events
Matrix Metalloproteinase 13 (MMP-13) Inhibitors - Drug Profile
Product Description
Mechanism Of Action
History of Events
pentosan polysulfate sodium - Drug Profile
Product Description
Mechanism Of Action
History of Events
Proteins for Rheumatoid Arthritis and Osteoarthritis - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit MMP 2,9 and 13 for Myocardial Infarction - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit MMP-13 for Osteoarthritis Pain and Inflammation - Drug Profile
Product Description
Mechanism Of Action
History of Events
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Dormant Products
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Discontinued Products
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Product Development Milestones
Featured News & Press Releases
Aug 08, 2022: MPS clinical program update and paradigm to present at the International Conference on lysosomal diseases
Jul 13, 2022: Paradigm partners with NFL Alumni Health on osteoarthritis program
Jul 06, 2022: Paradigm reports important global progress for the PARA_OA_002 phase 3 clinical trial evaluating Zilosul for osteoarthritis.
Jul 01, 2022: PARA_OA_008 study evaluating Zilosul mechanism and disease modifying effects completes recruitment
May 24, 2022: Paradigm Biopharmaceuticals spotlights potential breakthrough osteoarthritis treatment at Biological Association 3rd Annual Summit
May 05, 2022: Paradigm doses first subjects in Phase III knee osteoarthritis trial
Apr 13, 2022: FDA grants Fast Track Designation for Paradigm Biopharmaceuticals phase III osteoarthritis program
Mar 17, 2022: Paradigm Biopharmaceuticals initiates a phase 3 clinical trial in knee osteoarthritis across the U.S
Mar 17, 2022: Paradigm has received regulatory and ethics approvals for the PARA_OA_002 clinical trial in the UK.
Feb 11, 2022: International researchers highlight the need for PPS as a new adjunct therapy treatment for unmet needs of patients with MPS VI
Jan 13, 2022: First subjects randomised dosed in PARA_0A_002 phase 3 study in Australia
Jan 12, 2022: Paradigm presentation at the 40th Annual J.P. Morgan Healthcare Conference
Dec 16, 2021: PPS treatment demonstrates improvement in heart function and tissue preservation in preclinical heart failure model
Nov 23, 2021: Positive interim data from phase 2 rare disease trial presented at international medical congress
Nov 03, 2021: Paradigm’s Investigational New Drug (IND) application cleared by the US FDA.
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Aquilus Pharmaceuticals Inc, 2022
Pipeline by Avantyx Pharmaceuticals LLC, 2022
Pipeline by Paradigm Biopharmaceuticals Ltd, 2022
Pipeline by Pharmahungary Group, 2022
Pipeline by SteroTherapeutics LLC, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Discontinued Products, 2022
List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
Summary
According to the recently published report 'Collagenase 3 - Drugs In Development, 2022'; Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes.
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Collagenase-3 (MMP13) is a member of the matrix metalloproteinase (MMP) family of neutral endopeptidases. It plays a role in the degradation of extracellular matrix proteins including fibrillar collagen, fibronectin, TNC and ACAN, wound healing, tissue remodeling, cartilage degradation, bone development, bone mineralization and ossification.
The report 'Collagenase 3 - Drugs In Development, 2022' outlays comprehensive information on the Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Preclinical and Discovery stages are 1, 2 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Musculoskeletal Disorders, Cardiovascular, Central Nervous System, Genetic Disorders, Infectious Disease, Oncology, Respiratory and Toxicology which include indications Osteoarthritis, Osteoarthritis Pain, Allergic Asthma, Alphavirus Infections, Arthralgia (Joint Pain), Arthritis, Chemotherapy Induced Peripheral Neuropathy, Chikungunya Fever, Congestive Heart Failure (Heart Failure), Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome, Edema, Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ), Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ), Multiple Myeloma (Kahler Disease), Myocardial Infarction and Seasonal Allergic Rhinitis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.)
- The report reviews Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics and enlists all their major and minor projects
- The report assesses Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Overview
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Companies Involved in Therapeutics Development
Aquilus Pharmaceuticals Inc
Avantyx Pharmaceuticals LLC
Paradigm Biopharmaceuticals Ltd
Pharmahungary Group
SteroTherapeutics LLC
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Drug Profiles
Antisense RNAi Oligonucleotides to Inhibit MMP-13 for Osteoarthritis - Drug Profile
Product Description
Mechanism Of Action
Drug to Inhibit MMP-13 for Chemotherapy Induced Peripheral Neuropathy - Drug Profile
Product Description
Mechanism Of Action
History of Events
Matrix Metalloproteinase 13 (MMP-13) Inhibitors - Drug Profile
Product Description
Mechanism Of Action
History of Events
pentosan polysulfate sodium - Drug Profile
Product Description
Mechanism Of Action
History of Events
Proteins for Rheumatoid Arthritis and Osteoarthritis - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit MMP 2,9 and 13 for Myocardial Infarction - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit MMP-13 for Osteoarthritis Pain and Inflammation - Drug Profile
Product Description
Mechanism Of Action
History of Events
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Dormant Products
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Discontinued Products
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Product Development Milestones
Featured News & Press Releases
Aug 08, 2022: MPS clinical program update and paradigm to present at the International Conference on lysosomal diseases
Jul 13, 2022: Paradigm partners with NFL Alumni Health on osteoarthritis program
Jul 06, 2022: Paradigm reports important global progress for the PARA_OA_002 phase 3 clinical trial evaluating Zilosul for osteoarthritis.
Jul 01, 2022: PARA_OA_008 study evaluating Zilosul mechanism and disease modifying effects completes recruitment
May 24, 2022: Paradigm Biopharmaceuticals spotlights potential breakthrough osteoarthritis treatment at Biological Association 3rd Annual Summit
May 05, 2022: Paradigm doses first subjects in Phase III knee osteoarthritis trial
Apr 13, 2022: FDA grants Fast Track Designation for Paradigm Biopharmaceuticals phase III osteoarthritis program
Mar 17, 2022: Paradigm Biopharmaceuticals initiates a phase 3 clinical trial in knee osteoarthritis across the U.S
Mar 17, 2022: Paradigm has received regulatory and ethics approvals for the PARA_OA_002 clinical trial in the UK.
Feb 11, 2022: International researchers highlight the need for PPS as a new adjunct therapy treatment for unmet needs of patients with MPS VI
Jan 13, 2022: First subjects randomised dosed in PARA_0A_002 phase 3 study in Australia
Jan 12, 2022: Paradigm presentation at the 40th Annual J.P. Morgan Healthcare Conference
Dec 16, 2021: PPS treatment demonstrates improvement in heart function and tissue preservation in preclinical heart failure model
Nov 23, 2021: Positive interim data from phase 2 rare disease trial presented at international medical congress
Nov 03, 2021: Paradigm’s Investigational New Drug (IND) application cleared by the US FDA.
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Aquilus Pharmaceuticals Inc, 2022
Pipeline by Avantyx Pharmaceuticals LLC, 2022
Pipeline by Paradigm Biopharmaceuticals Ltd, 2022
Pipeline by Pharmahungary Group, 2022
Pipeline by SteroTherapeutics LLC, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Discontinued Products, 2022
List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
Related Report
